en
Scientific article
Open access
English

Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial

ContributorsFrisoni, Giovanni; NILVAD Study Group
Published inPLOS Medicine, vol. 15, no. 9, e1002660
Publication date2018
Abstract

This study reports the findings of the first large-scale Phase III investigator-driven clinical trial to slow the rate of cognitive decline in Alzheimer disease with a dihydropyridine (DHP) calcium channel blocker, nilvadipine. Nilvadipine, licensed to treat hypertension, reduces amyloid production, increases regional cerebral blood flow, and has demonstrated anti-inflammatory and anti-tau activity in preclinical studies, properties that could have disease-modifying effects for Alzheimer disease. We aimed to determine if nilvadipine was effective in slowing cognitive decline in subjects with mild to moderate Alzheimer disease.

Citation (ISO format)
FRISONI, Giovanni. Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial. In: PLOS Medicine, 2018, vol. 15, n° 9, p. e1002660. doi: 10.1371/journal.pmed.1002660
Main files (1)
Article (Published version)
Identifiers
ISSN of the journal1549-1277
321views
154downloads

Technical informations

Creation02/11/2019 5:49:00 PM
First validation02/11/2019 5:49:00 PM
Update time03/15/2023 4:20:51 PM
Status update03/15/2023 4:20:51 PM
Last indexation02/12/2024 11:39:57 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack